HWPC(SH:688799)2024-12-18 07:34Group 1: Company Overview - Warner Pharmaceuticals is listed under stock code 688799 and conducted investor relations activities on December 13 and 16, 2024 [2] - The company provided a brief introduction to its operational performance for the first three quarters of 2024 [2] Group 2: Regulatory and Research Updates - The National Medical Products Administration released guidelines for the development of artificial substitutes for endangered animal-based traditional Chinese medicine, requiring clinical trials in phases I, II, and III [3] - The company is collaborating with Hunan Tianji Rare Chinese Medicine Development Co., Ltd. on a project for an endangered animal medicine substitute, currently completing preclinical research [4] Group 3: Product Development and Clinical Trials - ZG-001, a new antidepressant capsule developed by a subsidiary, has completed phase I clinical trials and is intended for treating major depressive disorder [4] - Preclinical studies of ZG-001 showed promising antidepressant activity with rapid onset and lasting effects [5] Group 4: Market Performance and Sales - The sales of the company's sodium polystyrene sulfonate tablets have been increasing due to the establishment of a specialized service team in the digestive field [6] - The company has successfully participated in various centralized procurement programs, with multiple products winning bids in national and regional procurement initiatives [6]